LanguaTalk

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

S3-E4 - NASH-TAG 2022 Wrap-up: What Did We Learn about Fatty Liver Disease and Clinical Trial Design?

72 hours 52 mins; January 12, 2022

S3-E3 - NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing Methods

50 mins; January 09, 2022

S3-E2 - NASH-TAG 2022 Day 1 Summary: NASH Combination Therapies, Artificial Intelligence, Basic Science

78 hours 8 mins; January 08, 2022

S3-E1 - Previewing NASH-TAG 2022: Are we Ready To Pivot On Testing Methods like Histopathology?

51 mins; January 04, 2022

S2-E64.3 - SurfingNASH's 2021 NAFLD Year-In-Review Covers The Growing Energy and Impact of NASH Patient Advocacy

35 mins; January 02, 2022

S2-E64.2 - SurfingNASH's 2021 NAFLD Year-in-Review Covers the Emerging NAFLD Public Health Agenda

40 mins; January 02, 2022

S2-E64.1 - SurfingNASH's 2021 NAFLD Year-in-Review Explores Key NASH Themes of the Year Plus the Growth of Our Podcast

48 mins; January 01, 2022

S2-E64 - Stephen Harrison, Jeff Lazarus and Andrew Scott Join SurfingNASH.com's 2021 NAFLD Year-in-Review

61 hours 9 mins; December 31, 2021

S2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-Life

35 mins; December 30, 2021

S2-E63.2 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Multidisciplinary Initiatives and the Clinical Care Pathways Paper

33 mins; December 29, 2021

S2-E63.1 - SurfingNASH's 2021 NAFLD year-in-review Covers Cirrhosis Treatment Strategies Today and NASH Drugs in Development

35 mins; December 28, 2021

S2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-Review

62 hours 22 mins; December 27, 2021

S2-E62.3 - SurfingNASH's 2021 NAFLD year-in-review Covers the Patient-Advocate Initiated and Sponsored SUNN Study

31 mins; December 26, 2021

S2-E62.2 - SurfingNASH's 2021 NAFLD year-in-review Covers MRE and the Broader View of Non-Invasive Liver Testing

33 mins; December 24, 2021

S2-E62.1 - SurfingNASH's 2021 NAFLD year-in-review Covers AI in Histopathology

32 mins; December 23, 2021

S2-E62 - Mazen Noureddin, Alina Allen And Wayne Eskridge Join SurfingNASH's 2021 NAFLD Year-in-Review

57 mins; December 22, 2021

S2-E61.4 - How Might the Role of Bariatric Surgery Change post-SPLENDOR?

17 mins; December 19, 2021

S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

11 mins; December 19, 2021

S2-E61.2 - What does SPLENDOR Tell Us About the Impact of Bariatric surgery on Cardiovascular and Liver Events?

13 mins; December 18, 2021

S2-E61.1 - What does SPLENDOR Tell Us About MACE and MALO?

13 mins; December 18, 2021

SPLENDOR Study Lead Author Discusses The Effect Of Bariatric Surgery On MACE And MALO

61 hours 3 mins; December 15, 2021

S2-E60.3 - Previewing NASH-TAG 2022 Sessions 7-9 - Focus On Non-invasive Testing and Novel Targets

14 mins; December 12, 2021

S2-E60.2 - Previewing NASH-TAG 2022 Sessions 4-6 - Focus On the Major Consortia and Artificial Intelligence

15 mins; December 11, 2021

S2-E60.1 - Previewing NASH-TAG 2022 Sessions 1-3 -- Focus on Drug Development

13 mins; December 11, 2021

S2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 Preview

49 mins; December 08, 2021

S2-E59.4 - What Can We Do To Reshape a Potentially Disasatrous Growth in Cirrhosis?

15 mins; December 05, 2021

S2-E59.3 - What's next in Driving the Global Health Agenda for NAFLD?

15 mins; December 05, 2021

S2-E59.2 - Key Issues For the NAFLD Global Health Agenda: Prevalence and Cost Data

13 mins; December 04, 2021

S2-E59.1 - How the global Health Agenda for NAFLD Was Developed

12 mins; December 04, 2021

S2-E59 - Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey Lazarus

61 hours 0 mins; December 01, 2021

S2-E58.3 - Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE

21 mins; November 28, 2021

S2-E58.2 - Focus On NASH Cirrhosis: Reviewing FALCON 2 and the Belapectin Post Hoc Analysis of Phase 2 Data

16 mins; November 27, 2021

S2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLD

14 mins; November 27, 2021

S2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?

13 mins; November 22, 2021

S2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting Future

12 mins; November 21, 2021

S2-E57.2 - 2021 TLMdX From AASLD: The Path To Making NITs the "Gold Standard" for Drug Trials

12 mins; November 21, 2021

S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

18 mins; November 21, 2021

S2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdX

62 hours 22 mins; November 18, 2021

S2-E56 - Day Four at the 2021 TLMdX From AASLD

110 hours 45 mins; November 16, 2021

S2-E55 - Day Three at the 2021 TLMdX From AASLD

106 hours 46 mins; November 15, 2021

S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities

16 mins; November 13, 2021

S2-E54.2 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Perspectives

17 mins; November 13, 2021

S2-E54.1 - Inside the Patient-Focused Drug Development meeting: Stories of Personal Experiences

13 mins; November 13, 2021

S2-E54 - Go Inside a Pivotal Event: the NASH Patient-Focused Drug Development Meeting

55 mins; November 10, 2021

S2-E58 - What's New In Clinical Trials for NASH Cirrhosis

59 mins; November 10, 2021

S2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues

14 mins; November 07, 2021

S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

18 mins; November 07, 2021

S2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management Coverage

12 mins; November 06, 2021

S2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH Science

15 mins; November 06, 2021

S2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver Meeting

49 mins; November 03, 2021

S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint

19 mins; October 31, 2021

S2-E52.3 - Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?

12 mins; October 31, 2021

S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management

12 mins; October 30, 2021

S2-E52.1 - MRE Predicts Long-Term Progression and Outcomes in Chronic Liver Disease Patients

12 mins; October 30, 2021

S2-E52 - Predicting Long-Term Outcomes Using MR Elastography

58 mins; October 28, 2021

S2-E51.3 - More from Paris NASH: Overcoming Histopathology's flaws

14 mins; October 24, 2021

S2-E51.2 - More from Paris NASH: Precision Medicine's role in Drug Development and Patient Diagnosis

13 mins; October 23, 2021

S2-E51.1 - More from Paris NASH: precision Medicine, Stellate Cells and Hepatic Influencers

14 mins; October 23, 2021

S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Friedman

59 mins; October 20, 2021

S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future

13 mins; October 17, 2021

S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes

11 mins; October 16, 2021

S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution

14 mins; October 16, 2021

S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging

50 mins; October 13, 2021

S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?

18 mins; October 10, 2021

S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data

12 mins; October 09, 2021

S2-E49.1 - Clinical Care Pathway: How It Came To Be

15 mins; October 09, 2021

S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!

51 mins; October 06, 2021

S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?

11 mins; October 03, 2021

S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective

13 mins; October 03, 2021

S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"

12 mins; October 02, 2021

S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things

11 mins; October 02, 2021

S2-E48 - Closing Thoughts On an Eventful NASH Summer

50 mins; September 29, 2021

S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"

27 mins; September 26, 2021

S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."

22 mins; September 25, 2021

S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."

22 mins; September 25, 2021

S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer

73 hours 17 mins; September 23, 2021

S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots

14 mins; September 19, 2021

S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects

13 mins; September 18, 2021

S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis

12 mins; September 18, 2021

S2-E46 - Highlights from Paris NASH

48 mins; September 15, 2021

S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer

25 mins; September 12, 2021

S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.

26 mins; September 11, 2021

S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti

29 mins; September 11, 2021

S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer

75 hours 2 mins; September 09, 2021

S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?

11 mins; September 05, 2021

S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord

13 mins; September 05, 2021

S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries

13 mins; September 04, 2021

S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses

14 mins; September 04, 2021

S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH

62 hours 59 mins; September 01, 2021

S2-E43.4 -Rethinking Cirrhosis: A Call To Action

11 mins; August 29, 2021

S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development

12 mins; August 29, 2021

S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development

11 mins; August 28, 2021

S2-E43.1 - Cirrhosis - Challenges in Treating Patients

11 mins; August 28, 2021

S2-E43 - Can Cirrhosis Drive Drug Development In NASH?

53 mins; August 25, 2021

S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates

12 mins; August 22, 2021

S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH

12 mins; August 21, 2021

S2-E42.1 - FGF drugs in Development - A Promising Class of Agents

15 mins; August 21, 2021

S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?

50 mins; August 18, 2021

S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value

20 mins; August 15, 2021

S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH

12 mins; August 14, 2021

Click here to see more

Surfing the MASH Tsunami

Useful pages

Find a tutor

Languages